A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients

Evaluation of Xeljanz Access Barriers Via Patient OOP Costs and TNFi Cycling

This is a retrospective cohort study to evaluate patient characteristics, treatment patterns including a 6-factor effectiveness proxy measure, health care resource use and associated costs among Rheumatoid Arthritis patients initiating treatment comparator groups of interest between January 2014 and September 2016 across three United States insurance claims databases.

Inclusion Criteria:

• first pharmacy claim for Tofacitinib and then Etanercept or Adalimumab between Jan 2014 and Sep 2016 represents the index claim
• First, select patients receiving ≥1 Tofacitinib pharmacy claim (Jan 2014-Sep 2016) who did not have a Tofacitinib claim anytime prior to index
• Patients do have >1 advanced therapy filled on index date
• Physician diagnosis of Rheumatoid Arthritis (in any position) during the 1-year pre-index period, or on the index date
• Age 18+ years at index

Exclusion Criteria:

-None